Clinical utility of ctDNA was shown, both at pre-treatment by identifying a potential subgroup of ALK+ NSCLC patients who may derive more benefit from ensartinib and longitudinally by tracking resistance. Prospective application of this technology may translate to improved outcomes for NSCLC patients treated with ALK TKIs. READ ARTICLE
Journal of Thoracic Oncology DOI: 10.1016/j.jtho.2019.08.003
Authors: Leora Horn MD, Jennifer G. Whisenant PhD, Heather Wakelee MD, Karen L. Reckamp MD, Huan Qiao, MD PhD, Ticiana A. Leal MD, Liping Du PhD, Jennifer Hernandez BS, Vincent Huang BS, George R. Blumenschein MD, Saiama N. Waqar MD, Sandip P. Patel MD, Jorge Nieva MD, Geoffrey R. Oxnard MD, Rachel E. Sanborn MD, Tristan Shaffer, Kavita Garg, Allison Holzhausen MS, Kimberly Harrow MBA, Chris Liang PhD, Lee P. Lim PhD, Mark Li, Christine M. Lovly MD, PhD